Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2494
    -0.0017 (-0.13%)
     

  • Bitcoin GBP

    50,203.99
    -1,415.38 (-2.74%)
     

  • CMC Crypto 200

    1,306.23
    -90.30 (-6.47%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Global Oncology Molecular Diagnostics to 2027: U.S. Accounts for Over 28.8% in 2020, While China is Forecast to Grow at a 14.9% CAGR

Research and Markets
·4-min read

Dublin, Oct. 09, 2020 (GLOBE NEWSWIRE) -- The "Oncology Molecular Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Amid the COVID-19 crisis, the global market for Oncology Molecular Diagnostics estimated at US$1.7 Billion in the year 2020, is projected to reach a revised size of US$3.6 Billion by 2027, growing at a CAGR of 11.2% over the analysis period 2020-2027.

Breast Cancer, one of the segments analyzed in the report, is projected to grow at a 8.7% CAGR to reach US$900.3 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Colorectal Cancer segment is readjusted to a revised 14.5% CAGR for the next 7-year period. This segment currently accounts for a 25.8% share of the global Oncology Molecular Diagnostics market.

The U. S. Accounts for Over 28.8% of Global Market Size in 2020, While China is Forecast to Grow at a 14.9% CAGR for the Period of 2020-2027

The Oncology Molecular Diagnostics market in the U. S. is estimated at US$490.5 Million in the year 2020. The country currently accounts for a 28.84% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$669.6 Million in the year 2027 trailing a CAGR of 14.9% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.9% and 9.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.8% CAGR while Rest of European market (as defined in the study) will reach US$669.6 Million by the year 2027.

Prostate Cancer Segment Corners a 18.2% Share in 2020

In the global Prostate Cancer segment, USA, Canada, Japan, China and Europe will drive the 11.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$233.6 Million in the year 2020 will reach a projected size of US$506.2 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$533.5 Million by the year 2027, while Latin America will expand at a 14% CAGR through the analysis period.

The report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others:

  • Abbott Laboratories

  • Bayer Healthcare AG

  • Beckman Coulter, Inc.

  • Becton, Dickinson and Company

  • Cepheid, Inc.

  • Danaher Corporation

  • Hologic, Inc.

  • Leica Biosystems Inc.

  • Qiagen NV

  • Roche Diagnostics (Schweiz) AG

  • Siemens Healthineers

  • Sysmex Corporation

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Impact of Covid-19 and a Looming Global Recession

  • Global Competitor Market Shares

  • Oncology Molecular Diagnostics Competitor Market Share Scenario Worldwide (in %): 2018E

ADVERTISEMENT

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES

  • Market Facts & Figures

  • US Oncology Molecular Diagnostics Market Share (in %) by Company: 2018 & 2027

  • Market Analytics

CANADA

JAPAN

CHINA

EUROPE

  • Market Facts & Figures

  • European Oncology Molecular Diagnostics Market: Competitor Market Share Scenario (in %) for 2018 & 2027

  • Market Analytics

FRANCE

GERMANY

ITALY

UNITED KINGDOM

SPAIN

RUSSIA

REST OF EUROPE

ASIA-PACIFIC

AUSTRALIA

INDIA

SOUTH KOREA

REST OF ASIA-PACIFIC

LATIN AMERICA

ARGENTINA

BRAZIL

MEXICO

REST OF LATIN AMERICA

MIDDLE EAST

IRAN

ISRAEL

SAUDI ARABIA

UNITED ARAB EMIRATES

REST OF MIDDLE EAST

AFRICA

IV. COMPETITION

  • Total Companies Profiled: 42

For more information about this report visit https://www.researchandmarkets.com/r/8ukl9c

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900